People: Cidara Therapeutics Inc (CDTX.OQ)
22 Apr 2019
Mr. David L. Gollaher, Ph.D. is Director o the Company. Dr. Gollaher served as vice president of worldwide government affairs and policy for Gilead Sciences from early 2014 to mid-2018, a period during which the company launched a breakthrough cure for the hepatitis C virus (HCV) and tripled revenues from $10 billion to $30 billion. In addition to leading the introduction of three novel drugs for HCV, building on Gilead's strength in virology, he was involved in the launch of a new generation of medicines for HIV/AIDS. Prior to joining Gilead, Dr. Gollaher served for 20 years as co-founder and chief executive officer of the California Healthcare Institute (CHI). During this time, he built CHI into the nation's premier state-based life sciences policy research and advocacy association, representing nearly 370 biopharma, medical device and diagnostics companies, along with leading academic institutions, venture capital and professional services firms. Earlier in his career, Dr. Gollaher was vice president at Scripps Clinic and Research Foundation, responsible for managed care, strategy and corporate affairs. Additionally, in June of 2018, Dr. Gollaher was appointed a Senior Fellow at the Leonard D. Schaeffer Center for Health Policy and Economics at the University of Southern California. He also currently serves on Gilead's Health Policy Advisory Board and the Board of Overseers for The Scripps Research Institute. He earned a Bachelor of Arts degree from University of California Santa Barbara and both masters and doctorate degrees from Harvard University.
|Total Annual Compensation,||--|
|Restricted Stock Award,||--|
|Long-Term Incentive Plans,||--|
|Fiscal Year Total,||--|